Symbolbild · KI-generiert
Medicure Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT ® (tirofiban hydrochloride) injection and ZYPITAMAG ® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ('Marley Drug'), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug ® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. Medicure also operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near major transportation lines and multiple healthcare clinics and centers.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Medicure Inc. | MPH | TSXV | 10 Mio. USD |
| InnoCan Pharma Corporation | INNO | CSE | 9 Mio. USD |
| Rapid Dose Therapeutics Corp. | DOSE | CSE | 9 Mio. USD |
| Comprehensive Healthcare Systems Inc. | CHS | TSXV | 10 Mio. USD |
| 1CM Inc | EPIC | CSE | 9 Mio. USD |
| Seegnal Inc. | SEGN | TSXV | 9 Mio. USD |
| Frequency Exchange Corp. | FREQ | TSXV | 11 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.